Titelbild

Scientific Advisory Board

 
Portrait

Prof. Dr. Percy A. Knolle, Technical University Munich

Professor Knolle (b. 1962) carries out research on the molecular and cellular mechanisms of organ-specific immune regulation. The main emphasis of this work is on liver immunology. His research contributes to our understanding of the immune competence of peripheral organs and lays the foundation for novel immunotherapeutic approaches to target chronic liver infection and cancer.

After studying medicine at the universities of Frankfurt, Paris, Birmingham, Geneva and Strasbourg, Professor Knolle performed his doctoral studies at the German Cancer Research Center in Heidelberg. Having completed his training leading to German medical board certification in internal medicine/hepatology at the University Hospital of Mainz, he pursued a career in research at the Centre for Molecular Biology in Heidelberg. In 2002 he set up the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn. Since 2013 he has served as founding director of the Institute of Molecular Medicine (MOMENTUM) at the TUM School of Medicine.

 
Portrait

Prof. Dr. Percy A. Knolle, Technical University Munich

Professor Knolle (b. 1962) carries out research on the molecular and cellular mechanisms of organ-specific immune regulation. The main emphasis of this work is on liver immunology. His research contributes to our understanding of the immune competence of peripheral organs and lays the foundation for novel immunotherapeutic approaches to target chronic liver infection and cancer.

After studying medicine at the universities of Frankfurt, Paris, Birmingham, Geneva and Strasbourg, Professor Knolle performed his doctoral studies at the German Cancer Research Center in Heidelberg. Having completed his training leading to German medical board certification in internal medicine/hepatology at the University Hospital of Mainz, he pursued a career in research at the Centre for Molecular Biology in Heidelberg. In 2002 he set up the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn. Since 2013 he has served as founding director of the Institute of Molecular Medicine (MOMENTUM) at the TUM School of Medicine.

 
Portrait

Prof. Dr. Horst Weller, University Hamburg

Horst Weller studied Chemistry in Göttingen and went to the Hahn-Meitner Institute in Berlin for his post-doc. Nanoparticles had just emerged at that time and were investigated for catalytic application at this institute; insofar Horst Weller is a nanotechnologist of the first hour contributing to its knowledge and wide spread use. At the University of Hamburg Horst Weller and his group developed nanotechnology into a truly interdisciplinary science with numerous applications in chemistry, material sciences and life sciences. Next to his professorship at the University of Hamburg Horst Weller also is the Scientific Director of the Center for Applied Nanotechnology (CAN) in Hamburg.

 
Portrait

Prof. Dr. Horst Weller, University Hamburg

Horst Weller studied Chemistry in Göttingen and went to the Hahn-Meitner Institute in Berlin for his post-doc. Nanoparticles had just emerged at that time and were investigated for catalytic application at this institute; insofar Horst Weller is a nanotechnologist of the first hour contributing to its knowledge and wide spread use. At the University of Hamburg Horst Weller and his group developed nanotechnology into a truly interdisciplinary science with numerous applications in chemistry, material sciences and life sciences. Next to his professorship at the University of Hamburg Horst Weller also is the Scientific Director of the Center for Applied Nanotechnology (CAN) in Hamburg.

 
Portrait

Prof. Dr. Thomas Jung, Auris Medical

Thomas Jung, MD/PhD, is a physician-scientist experienced in Translational Sciences, Preclinical and Clinical Development of small molecules as well as biologics. His current role is Chief Development Officer at Auris Medical, Basel, Switzerland after having been Chief Medical Officer for Delenex Therapeutics, Zürich, Switzerland. Before that, Thomas was a member of Novartis’ R&D Group for a total of 13 years. His most recent role there was Head of Translational Medicine EU at Novartis, Basel, Switzerland. Thomas acts as a member of the Supervisory Board for AIMM Therapeutics, Amsterdam, The Netherlands. He is a board certified Dermatologist holding an Associate Professor position for Dermatology at the University of Göttingen, Germany.

 
Portrait

Prof. Dr. Thomas Jung, Auris Medical

Thomas Jung, MD/PhD, is a physician-scientist experienced in Translational Sciences, Preclinical and Clinical Development of small molecules as well as biologics. His current role is Chief Development Officer at Auris Medical, Basel, Switzerland after having been Chief Medical Officer for Delenex Therapeutics, Zürich, Switzerland. Before that, Thomas was a member of Novartis’ R&D Group for a total of 13 years. His most recent role there was Head of Translational Medicine EU at Novartis, Basel, Switzerland. Thomas acts as a member of the Supervisory Board for AIMM Therapeutics, Amsterdam, The Netherlands. He is a board certified Dermatologist holding an Associate Professor position for Dermatology at the University of Göttingen, Germany.

 
Portrait

Prof. Dr. Johannes Herkel, University Medical Centre Hamburg-Eppendorf (UKE)

Johannes Herkel is professor at the Department of Medicine I at the University Medical Centre Hamburg-Eppendorf (UKE). Prof. Herkel is co-inventor of the Topas tolerogenic technology platform. His major scientific interests are the regulation of immune responses in the liver, the pathogenesis of autoimmune diseases and the identification of mechanisms and molecules that control the activity of the immune system. The ultimate goal of his research activities is the development of treatments for immune-mediated disorders.

 
Portrait

Prof. Dr. Johannes Herkel, University Medical Centre Hamburg-Eppendorf (UKE)

Johannes Herkel is professor at the Department of Medicine I at the University Medical Centre Hamburg-Eppendorf (UKE). Prof. Herkel is co-inventor of the Topas tolerogenic technology platform. His major scientific interests are the regulation of immune responses in the liver, the pathogenesis of autoimmune diseases and the identification of mechanisms and molecules that control the activity of the immune system. The ultimate goal of his research activities is the development of treatments for immune-mediated disorders.